cas 915087-26-2|| where to buy 4-((1-cyanocyclobutyl)amino)-2-fluoro-N-methylbenzamide

Product Name:4-((1-cyanocyclobutyl)amino)-2-fluoro-N-methylbenzamide

IUPAC Name:4-[(1-cyanocyclobutyl)amino]-2-fluoro-N-methylbenzamide

Packing Unit	Available Stock	Price($)
CM201573-10g	in stock	ȯŸ
CM201573-25g	in stock	ƚŞȯ
CM201573-100g	in stock	ǫȖŪ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 915087-26-2 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:915087-26-2; Molecular Formula:C13H14FN3O; Melting Point:-; Smiles Code:O=C(NC)C1=CC=C(NC2(C#N)CCC2)C=C1F; Density:

: Catalog Number:CM201573; Molecular Weight:247.27; Boiling Point:; MDL No:MFCD09909370; Storage:Store at 2-8°C.

: Cyclobutanes; The molecular structure of cyclobutane has four carbon atoms, and its four carbon atoms are not in the same plane, which is the folded conformation of cyclobutane. Cyclobutane itself is not of commercial or biological interest, but more complex derivatives are important in biology and biotechnology. Currently, nine FDA-approved drugs contain the cyclobutane structure. From the perspective of therapeutic areas, cyclobutyl drugs are mainly distributed in popular areas such as tumors, neurological diseases, infectious diseases, endocrine and metabolic diseases.

: Apalutamide; Johnson & Johnson announced results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone radical prostatectomy (RP). Following RP, patients who received the treatment regimen showed a 100% biochemical recurrence (BCR)–free rate at 24 months. ERLEADA® (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.